[Pubmed] Immune Checkpoint Inhibitor-induced Myositis

[RSS-Bot]

Rheum Dis Clin North Am. 2024 May;50(2):281-290. doi: 10.1016/j.rdc.2024.02.003. Epub 2024 Mar 12.

ABSTRACT

Myositis induced by immune checkpoint inhibitors (ICIs) is an infrequent, potentially fatal, immune-related adverse event. It has higher incidence in patients who receive combination ICI therapy compared to monotherapy. Patients can present with clinical manifestation symptoms of myositis alone or in combination with myocarditis and/or myasthenia gravis, which significantly worsens the course and prognosis. Diagnosis can generally be made on the basis of clinical presentation, elevation of muscle enzymes, and electromyographic changes, but some patients may require a muscle biopsy. The first line of therapy is high-dose corticosteroids, followed by immunosuppression, plasmapheresis, or intravenous immunoglobulin in patients with severe disease.

PMID:38670726 | DOI:10.1016/j.rdc.2024.02.003


Source: https://pubmed.ncbi.nlm.nih.gov/3867072 ... t9+e462414